HIGHLIGHTS
- who: Taihang Shao et al. from the squamous cell carcinoma, Orient, ChinaAnhui Medical University, China have published the research work: Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma, in the Journal: (JOURNAL)
- what: In the study , only direct medical costs were considered, including costs of acquiring drugs, costs attributed to the patient`s diagnosis and hospitalization, costs for the management of adverse events (AEs), and costs for end-of-life care (Eol) were analyzed. Frontiers in Oncology frontiersin.org . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.